 Polypeptides useful as immunotherapeutic agents and methods of polypeptide preparation |
| What is claimed is: 1. An immunogenic composition suitable for administration by injection, which ... |
|
| Methods for introducing mannose 6-phosphate and other oligosaccharides onto glycoproteins |
| Methods of creating neoglycoproteins are provided that increase the cellular uptake of lysosomal ... |
|
| Recombinant avipox virus and immunological use thereof |
| What is claimed is: 1. A method for inducing an immunological response in a mammal to a mammalian ... |
|
| HIV protease inhibitors useful for the treatment of AIDS |
| OF THE INVENTION AND PREFERRED EMBODIMENTS This invention is concerned with compounds of formula I,... |
|
| Benzoxazinones as inhibitors of HIV reverse transcriptase |
| OF THE INVENTION AND PREFERRED EMBODIMENTS This invention is concerned with compounds of formula I,... |
|
| HIV protease inhibitors useful for the treatment of AIDS |
| OF THE INVENTION AND PREFERRED EMBODIMENTS This invention is concerned with compounds of Formula I,... |
|
| Continuously operational biological reactor |
| The present invention comprehends a continuously operable biological reactor for processing animal ... |
|
| Separating epithelium from stroma in LASEK surgery |
| A surgical method according to the invention includes application of a solution containing ethanol ... |
|
| Glucaric acid monoamides and their use to prepare poly(glucaramides) |
| OF THE INVENTION The novel alkali metal N-aminohydrocarbyl- and N-aminoheterohydrocarbyl-D-... |
|
|
Product and method for control of obesity
| Details |
Inventors: Belyea, Christopher Ian; Ng, Frank Man-Woon; Vaughan, Paul;
Assignee: Metabolic Pharmaceuticals Limited (Toorak, AU)
Primary Examiner: Mehta; Ashwin D.
Assistant Examiner: Worley; Cathy Kingdon
Attorney, Agent or Firm: Klarquist Sparkman, LLP
The invention relates to food and beverage products which are useful in control of obesity. The food or beverage comprises or is made by a transgenic plant or parts thereof comprising a nucleic acid molecule, the nucleic acid molecule encoding a C-terminal growth hormone fragment which has the ability to modulate lipid metabolism. The transgenic plant may be used in a production of a fermented food or beverage product, or may be a part of an edible plant, such as a fruit or vegetable, including but not limited to tomato, banana, and potato. |
|
DETAILED DESCRIPTION The invention claimed is: 1.
A transgenic plant comprising a first exogenous nucleic acid molecule which encodes a peptide corresponding to a mammalian growth hormone fragment and comprising a disulphide bond, wherein said peptide includes amino acid residues 177 191 of human growth hormone, (amino acids 2 16 of SEQ ID NO:9), a subfragment thereof, or an analogue thereof, wherein the analogue varies at no more than three positions from SEQ ID NO:9 and wherein the analogue contains an arginine at the position corresponding to position 3 of SEQ ID NO:9, and wherein the analogue contains a glutamic acid at the position corresponding to position 11 of SEQ ID NO:9, with the provision that any analogue is not intact, full-length growth hormone polypeptide, and in which the peptide, subfragment, or analogue is orally active and has the ability to increase lipolysis or decrease lipogenesis in a mammal to which the transgenic plant or a part or product thereof is orally administered.
2.
A transgenic plant according to claim 1, in which the peptide, subfragment or analogue has the ability to stimulate the activity of hormone-sensitive lipase, and to inhibit acetyl CoA carboxylase.
3.
A transgenic plant according to claim 1, in which the peptide, subfragment or analogue has the ability to reduce lipogenic activity.
4.
A transgenic plant according to claim 1, in which the peptide, subfragment or analogue has the ability to stimulate lipolysis.
5.
A transgenic plant according to claim 1, in which the first exogenous nucleic acid molecule encodes a peptide comprising amino acids 7 14 of SEQ ID NO:9 (hGH 182 189).
6.
A transgenic plant according to claim 1, in which the first exogenous nucleic acid molecule encodes a peptide consisting of a methionine residue immediately followed by the amino acids from positions 2 16 of SEQ ID NO:9 (hGH 177 191).
7.
A transgenic plant according to claim 1, in which the first nucleic acid molecule is operably linked to a second exogenous nucleic acid molecule encoding a heterologous fusion partner which is a signal sequence for a secreted polypeptide or protein
|
|
Gene Therapy 
